Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus cemiplimab in relapsed or refractory lymphoma
NL-OMON48105Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of isatuximab and cemiplimab in classical Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL) (5 arms), sponsored by Sanofi. Primary endpoints: Dose-limiting toxicities, Recommended Phase 2 dose and 2 more. Started Aug 2019; status: active, not recruiting.
02
Drugs
isatuximabcemiplimab
03
Conditions
classical Hodgkin lymphoma (cHL)diffuse large B-cell lymphoma (DLBCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NL-OMON48105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48105.